Pharma major Novartis falls 10% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors. This story matters for Finance & Markets readers tracking bond. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BondNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily bond signal